Navigation Links
YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
Date:1/5/2009

    Singapore investigators to coordinate 700 patient trial of EGFR targeting
    antibody for treatment of head and neck cancer

MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that the National Cancer Centre of Singapore (NCCS) has selected nimotuzumab, YM's EGFR-targeting drug, for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck. The NCCS stated that it selected nimotuzumab because of its reported preferential safety profile compared with other EGFR-targeting cancer drugs. The trial is sponsored by the NCCS in collaboration with Innogene Kalbiotech Pte. Ltd, ("IGK") YM's licensee for nimotuzumab for the region.

"The efficacy of nimotuzumab as an epidermal growth factor receptor targeted therapy is likely to be comparable to drugs of the same class. However, what is likely to set nimotuzumab apart is its low toxicity and favourable safety profile," said Dr. Rikrik Ilyas, Director of IGK. "Patients are spared the discomfort of severe skin rashes and may benefit from an enhanced quality of life. Both patients and physicians may also benefit from lack of hypomagnesemia often related to treatment with other anti-EGFR targeted drugs. IGK is pleased to support the NCCS in this investigator-initiated trial of nimotuzumab."

The NCCS is the lead cancer centre coordinating this clinical trial, which will involve approximately 22 institutions from 12 countries worldwide. The trial will treat patients with locally advanced squamous cell cancers of the head and neck immediately following surgery - the "adjuvant setting". Along with standard chemotherapy and radiotherapy, half of the patients will be administered nimotuzumab weekly for an eight week period. The primary endpoint for th
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Md. , Nov. 24, 2014  Spherix ... development company committed to the fostering and monetization ... Spherix v. VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M ... Case No. 3:13-cv-03496-M, both in the United States ... Texas . On ...
(Date:11/23/2014)... 23, 2014 Apiscent Labs, a ... fine chemical ingredients to the global pharmaceutical and ... its new website, Apiscent.com. , The Apiscent.com homepage ... clean design, easy navigation, rotating images and content ... stand out. , The company’s work ...
(Date:11/22/2014)... 21, 2014 During his lifetime Richard ... need to surround himself with great people and take ... his friends often marveled at his extraordinarily courageous attitude ... life and -- even with his death impending—that’s how ... disease that would ultimately take his life. , Carrying ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 CannLabs, ... cloud based analytics and scientific testing methodologies relating to ... for a $750,000 line of credit from an existing ... pleased to have secured this commitment from one of ... Officer of CannLabs. “This capital will help accelerate our ...
Breaking Biology Technology:Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3CannLabs Secures $750,000 Line Of Credit 2
... April 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... research group at St. James,s University Hospital in ... reovirus in the May 1, 2008,online issue of ... "Reovirus,Activates Human Dendritic Cells to Promote Innate Antitumor ...
... SectorWatch.biz announces the,availability of MarketStats on ... today within the biotechnology and diagnostic testing ... equities and the,opportunity for investors to respond ... sector., Investors can view SectorWatch.biz MarketStats ...
... Company Increases Focus on PMA Study, FORT ... (OTC Bulletin Board: IMDS) announced that on,April 16, ... of its,three outside directors Jay Bendis, Patrick Gorman, ... with a request by outside,funding sources as a ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells 2SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT 2SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT 3Imaging Diagnostic Systems Accepts Resignations of Outside Directors 2Imaging Diagnostic Systems Accepts Resignations of Outside Directors 3
(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has announced ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo ... In its first six months of existence, the Lab has ... support for local law enforcement. "Because our number ...
(Date:11/6/2014)... Fla. -- A groundbreaking paper from a team of ... understanding of how plants could adapt to and survive ... research, published in the latest issue of the journal ... chromatin (the complex of DNA and proteins) is organized ... so that some genes are turned on and others ...
(Date:11/6/2014)... when that predator runs so fast that it essentially blinds ... the fastest creature on Earth. Some of these half-inch-long beetles ... miles per hour). The fastest human can do about five ... beetle, a person would have to hit 480 miles per ... peak speeds, everything becomes a blur. They can,t gather enough ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Maize analysis yields whole new world of genetic science 2The tiger beetle: Too fast to see 2
... is launching the first integrated, drug development pipeline ... diseases. The $24 million program jumpstarts a trans-NIH ... Diseases Program, or TRND. , The program, ... TRND creates a drug development pipeline within the ...
... rapid growth of institutional Memberships for open access ... of the "Online Reporting System" for its open ... BioMed Central,s cutting edge publishing platform, the new ... and help reduce the administrative costs associated with ...
... personal care products (PPCPs) carried in biosolids (i.e., ... groundwater when these materials are applied as fertilizer ... created by land application of liquid municipal biosolids ... macropores may be too short for sorption equilibration ...
Cached Biology News:NIH announces new program to develop therapeutics for rare and neglected diseases 2NIH announces new program to develop therapeutics for rare and neglected diseases 3NIH announces new program to develop therapeutics for rare and neglected diseases 4NIH announces new program to develop therapeutics for rare and neglected diseases 5Simulating pharmaceutical and personal care product transport 2
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known arabidopsis microRNAs ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Viruses microRNA Microarray ...
Biology Products: